SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy SLS?
Source: stocktwits
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.220
Low
7.00
Averages
7.25
High
7.50
Current: 5.220
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Stock Soars 25% Amid Institutional Buying and AML Data Catalyst
- Stock Surge: Sellas Life Sciences' shares soared 25% on Wednesday, marking its best single-day performance in over two months, primarily driven by BlackRock's 62% stake increase, reflecting strong market confidence in the company.
- Clinical Trial Progress: As of May 11, Sellas' Phase 3 Regal AML study reached 78 events, just two away from final data disclosure, with the CEO highlighting this moment as crucial for potential transformative treatment for AML patients.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and equivalents and secured an additional $7.5 million from warrant exercises in Q2, while establishing a new at-the-market equity facility to raise up to $150 million, although no shares have been sold yet.
- Second AML Program: Sellas' second AML program, SLS009, has begun dosing newly diagnosed high-risk patients in a Phase 2 study, with early data showing promising effects on AML cells, and topline data expected in Q4, further enhancing market anticipation.
See More
Nebius Reports 654% Revenue Surge; Cisco Raises AI Order Forecast to $9 Billion
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year increase in Q1 revenue, reaching $399 million, surpassing Wall Street's estimate of $388 million, indicating strong demand in AI infrastructure, with a projected annual recurring revenue of $7 billion to $9 billion for 2026, solidifying its market position.
- Cisco AI Order Forecast Raised: Cisco raised its AI-related infrastructure order forecast for 2026 from $5 billion to $9 billion, reflecting robust demand for AI hardware, while reporting a 12% increase in Q3 revenue to $15.8 billion, exceeding analyst expectations, showcasing the company's success in its transformation.
- Sellas Cancer Research Progress: Sellas Life Sciences updated on its Phase 3 REGAL study for acute myeloid leukemia, nearing the final event threshold for key data readout, and has initiated a Phase 2 trial for high-risk AML patients, demonstrating its potential in cancer treatment.
- Strong Stock Market Performance: Stocks of Nebius, Cisco, and Sellas reached fresh 52-week highs, with gains of over 147%, 32%, and 73% respectively, as investors recognized tangible progress in AI infrastructure and drug development, with retail sentiment shifting to 'extremely bullish'.
See More
U.S. Stocks Hit Record Highs, Tech Stocks Lead Gains
- Tech Stock Surge: The Nasdaq rose 1.4% and the S&P 500 gained 0.6%, both reaching record highs, indicating strong performance in tech stocks, particularly with NVIDIA hitting all-time highs, reflecting increased investor confidence in the technology sector.
- Rising Inflation Pressures: The producer price index surged 6% year-over-year in April, marking the highest level in four years and the sharpest monthly increase since 2022, indicating heightened cost pressures for producers that could influence future monetary policy and raise concerns about interest rate hikes.
- New Fed Chair Confirmation: The U.S. Senate confirmed Kevin Warsh as the 17th chair of the Federal Reserve, and while he advocates for lower rates, the current inflation signals have led to market uncertainty regarding future policy directions, potentially increasing market volatility.
- Energy Market Trends: Brent crude oil prices settled near $104.85 per barrel, as fears of rising U.S. interest rates dampened global demand outlook; however, the International Energy Agency warned that global oil supply could remain below demand until 2026 due to ongoing disruptions in the Middle East.
See More
SELLAS Life Sciences Stock Surges Nearly 30% This Week
- Stock Performance: SELLAS Life Sciences (SLS) has surged nearly 30% this week, on track for its best weekly performance since January 2, indicating strong market confidence in its future prospects.
- Clinical Trial Progress: The company is advancing key programs in acute myeloid leukemia (AML), with the pivotal REGAL trial just two events away from data analysis, as of May 11, 2026, 78 deaths have occurred in the study, with the prespecified 80th event set to trigger results analysis.
- Analyst Ratings: According to Koyfin data, both analysts covering SELLAS rate it ‘Buy’ or higher, with a 12-month average price target of $10, representing a potential upside of about 53% from Wednesday's closing price, reflecting optimistic market expectations for its future performance.
- Retail Sentiment: On Stocktwits, retail sentiment around SELLAS has remained in the ‘bullish’ territory, with message volume increasing from ‘normal’ to ‘high’ levels over the past 24 hours, indicating heightened investor interest and anticipation for the upcoming trial results.
See More
SELLAS Life Sciences Shares Rise 16% on Trial Progress
- Clinical Trial Progress: SELLAS Life Sciences revealed in its Q1 2026 report that its pivotal REGAL Phase 3 trial is nearing final analysis, having recorded 78 events, just two short of the 80-event trigger point, which could lead to significant advancements in acute myeloid leukemia (AML) treatment.
- Strong Financial Position: As of March 31, 2026, SELLAS reported approximately $107.1 million in cash and cash equivalents, reflecting a nearly 49% increase from December 31, 2025, providing ample funding for ongoing clinical trials and research initiatives.
- New Drug Development: The company also announced that dosing has commenced in a Phase 2 trial for its second most advanced candidate, SLS009, aimed at providing a first-line treatment option for AML patients unlikely to benefit from standard care, thereby expanding its product pipeline.
- Optimistic Market Outlook: CEO Angelos Stergiou stated that with the critical results from the REGAL trial approaching and the advancement of SLS009, SELLAS is entering a promising phase with multiple high-value catalysts that could transform the AML treatment landscape.
See More
Oil Prices Surge as Markets Eye Trump-Xi Summit
- Oil Price Surge: Brent crude prices are nearing $107 per barrel and WTI above $102, having risen nearly 8% over the past three sessions, which pressures market sentiment, particularly following Trump's criticism of the U.S.-Iran ceasefire agreement.
- Market Reaction: U.S. stock futures edged higher late Tuesday, with Nasdaq 100 futures up 0.2% and S&P 500 futures gaining 0.1%, while Dow futures dipped slightly, reflecting investor caution ahead of key inflation data.
- Trump-Xi Summit: The anticipated summit between Trump and Xi on May 14-15 is expected to focus on trade negotiations despite ongoing tensions in Iran, with markets hopeful for outcomes that could stabilize oil prices and enhance trade relations, given China's significant oil imports from Iran.
- Economic Indicators Watch: Markets are closely monitoring the upcoming producer price index (PPI) report, with expectations for a 0.5% month-over-month increase in April's PPI and a 0.3% rise in core PPI, which could influence the Federal Reserve's monetary policy direction.
See More
Sellas Life Sciences Stock Soars 25% Amid Institutional Buying and AML Data Catalyst
- Stock Surge: Sellas Life Sciences' shares soared 25% on Wednesday, marking its best single-day performance in over two months, primarily driven by BlackRock's 62% stake increase, reflecting strong market confidence in the company.
- Clinical Trial Progress: As of May 11, Sellas' Phase 3 Regal AML study reached 78 events, just two away from final data disclosure, with the CEO highlighting this moment as crucial for potential transformative treatment for AML patients.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and equivalents and secured an additional $7.5 million from warrant exercises in Q2, while establishing a new at-the-market equity facility to raise up to $150 million, although no shares have been sold yet.
- Second AML Program: Sellas' second AML program, SLS009, has begun dosing newly diagnosed high-risk patients in a Phase 2 study, with early data showing promising effects on AML cells, and topline data expected in Q4, further enhancing market anticipation.
See More
Nebius Reports 654% Revenue Surge; Cisco Raises AI Order Forecast to $9 Billion
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year increase in Q1 revenue, reaching $399 million, surpassing Wall Street's estimate of $388 million, indicating strong demand in AI infrastructure, with a projected annual recurring revenue of $7 billion to $9 billion for 2026, solidifying its market position.
- Cisco AI Order Forecast Raised: Cisco raised its AI-related infrastructure order forecast for 2026 from $5 billion to $9 billion, reflecting robust demand for AI hardware, while reporting a 12% increase in Q3 revenue to $15.8 billion, exceeding analyst expectations, showcasing the company's success in its transformation.
- Sellas Cancer Research Progress: Sellas Life Sciences updated on its Phase 3 REGAL study for acute myeloid leukemia, nearing the final event threshold for key data readout, and has initiated a Phase 2 trial for high-risk AML patients, demonstrating its potential in cancer treatment.
- Strong Stock Market Performance: Stocks of Nebius, Cisco, and Sellas reached fresh 52-week highs, with gains of over 147%, 32%, and 73% respectively, as investors recognized tangible progress in AI infrastructure and drug development, with retail sentiment shifting to 'extremely bullish'.
See More
U.S. Stocks Hit Record Highs, Tech Stocks Lead Gains
- Tech Stock Surge: The Nasdaq rose 1.4% and the S&P 500 gained 0.6%, both reaching record highs, indicating strong performance in tech stocks, particularly with NVIDIA hitting all-time highs, reflecting increased investor confidence in the technology sector.
- Rising Inflation Pressures: The producer price index surged 6% year-over-year in April, marking the highest level in four years and the sharpest monthly increase since 2022, indicating heightened cost pressures for producers that could influence future monetary policy and raise concerns about interest rate hikes.
- New Fed Chair Confirmation: The U.S. Senate confirmed Kevin Warsh as the 17th chair of the Federal Reserve, and while he advocates for lower rates, the current inflation signals have led to market uncertainty regarding future policy directions, potentially increasing market volatility.
- Energy Market Trends: Brent crude oil prices settled near $104.85 per barrel, as fears of rising U.S. interest rates dampened global demand outlook; however, the International Energy Agency warned that global oil supply could remain below demand until 2026 due to ongoing disruptions in the Middle East.
See More
SELLAS Life Sciences Stock Surges Nearly 30% This Week
- Stock Performance: SELLAS Life Sciences (SLS) has surged nearly 30% this week, on track for its best weekly performance since January 2, indicating strong market confidence in its future prospects.
- Clinical Trial Progress: The company is advancing key programs in acute myeloid leukemia (AML), with the pivotal REGAL trial just two events away from data analysis, as of May 11, 2026, 78 deaths have occurred in the study, with the prespecified 80th event set to trigger results analysis.
- Analyst Ratings: According to Koyfin data, both analysts covering SELLAS rate it ‘Buy’ or higher, with a 12-month average price target of $10, representing a potential upside of about 53% from Wednesday's closing price, reflecting optimistic market expectations for its future performance.
- Retail Sentiment: On Stocktwits, retail sentiment around SELLAS has remained in the ‘bullish’ territory, with message volume increasing from ‘normal’ to ‘high’ levels over the past 24 hours, indicating heightened investor interest and anticipation for the upcoming trial results.
See More
SELLAS Life Sciences Shares Rise 16% on Trial Progress
- Clinical Trial Progress: SELLAS Life Sciences revealed in its Q1 2026 report that its pivotal REGAL Phase 3 trial is nearing final analysis, having recorded 78 events, just two short of the 80-event trigger point, which could lead to significant advancements in acute myeloid leukemia (AML) treatment.
- Strong Financial Position: As of March 31, 2026, SELLAS reported approximately $107.1 million in cash and cash equivalents, reflecting a nearly 49% increase from December 31, 2025, providing ample funding for ongoing clinical trials and research initiatives.
- New Drug Development: The company also announced that dosing has commenced in a Phase 2 trial for its second most advanced candidate, SLS009, aimed at providing a first-line treatment option for AML patients unlikely to benefit from standard care, thereby expanding its product pipeline.
- Optimistic Market Outlook: CEO Angelos Stergiou stated that with the critical results from the REGAL trial approaching and the advancement of SLS009, SELLAS is entering a promising phase with multiple high-value catalysts that could transform the AML treatment landscape.
See More
Oil Prices Surge as Markets Eye Trump-Xi Summit
- Oil Price Surge: Brent crude prices are nearing $107 per barrel and WTI above $102, having risen nearly 8% over the past three sessions, which pressures market sentiment, particularly following Trump's criticism of the U.S.-Iran ceasefire agreement.
- Market Reaction: U.S. stock futures edged higher late Tuesday, with Nasdaq 100 futures up 0.2% and S&P 500 futures gaining 0.1%, while Dow futures dipped slightly, reflecting investor caution ahead of key inflation data.
- Trump-Xi Summit: The anticipated summit between Trump and Xi on May 14-15 is expected to focus on trade negotiations despite ongoing tensions in Iran, with markets hopeful for outcomes that could stabilize oil prices and enhance trade relations, given China's significant oil imports from Iran.
- Economic Indicators Watch: Markets are closely monitoring the upcoming producer price index (PPI) report, with expectations for a 0.5% month-over-month increase in April's PPI and a 0.3% rise in core PPI, which could influence the Federal Reserve's monetary policy direction.
See More
